Navigating Non-Product Software Validation in GxP Environments
Navigating Non-Product Software Validation in GxP Environments
Yashaswini Maregowda
May 11, 2026
Table of Contents
1. Introduction
When life sciences organizations talk about software validation, the conversation always gravitates toward product software, embedded device firmware, or clinical trial software that touches the regulated product directly.
There is an equally important category of GxP software that underpins every regulated operation: non-product software. It includes laboratory information management systems (LIMS), quality management systems (QMS), document management platforms, training systems, and AI-driven analytical tools. Even without being part of the product itself, this software must still be validated.
What this blog covers
Your roadmap through this post
- Common Expectations
- Why It Matters
- Practical Roadmap
2. What Is Non-Product Software?
Non-product software is any software used in a GxP-regulated environment that does not become part of the product and is not embedded in a medical device. Despite this distinction, it directly influences product quality, patient safety, and data integrity, which is precisely why it falls within the scope of regulatory oversight.
Examples include:
- Quality Management Systems (QMS): CAPA management, deviation tracking, document control, training management, audit management platforms
- Laboratory Systems: LIMS, electronic lab notebooks (ELN), chromatography data systems (CDS)
- Manufacturing Systems: MES, SCADA, building management systems, batch record systems, ERP modules governing GxP operations
- Regulatory & Submission Support Tools: AI/ML models used to analyze manufacturing data, generate statistical summaries, or support regulatory submissions
- Infrastructure & Supporting Software: Backup and restore systems, access management platforms, audit trail repositories, archival systems
3. Overlapping Common Expectations
Common Expectations
The 10 Common Expectations
- Risk-Based Validation & Classification
- Requirements Management & Lifecycle Traceability
- Change Control & Impact Assessment
- Audit Trail & Electronic Records Integrity
- Testing Strategy Proportionate to Risk
- Document Lifecycle & Version Control
- Role-Based Access Control (RBAC)
- Incident Management & CAPA
- Vendor & Supplier Qualification
- Periodic Review & Continued State of Control
Risk-Based Validation & Classification
- FDA CSA replaces the old "validate everything to the same standard" model with a critical-thinking, risk-driven approach.
- GAMP5 uses its well-established software category framework to stratify validation effort by system complexity and criticality.
- ISO 13485 requires that software used in production and service provision be validated prior to use, with the extent of validation activities proportionate to the risk associated with the software's use.
Requirements Management & Full Lifecycle Traceability
- GAMP5 mandates a User Requirements Specification (URS) as the foundation of the validation lifecycle and requires traceability matrices linking requirements to test evidence.
- ISO 13485 requires documented design inputs and outputs with demonstrable traceability between them.
Change Control & Impact Assessment
- FDA CSA requires that changes be assessed for their potential impact on system performance and data integrity.
- GAMP5 provides detailed guidance on change impact categories and the corresponding re-validation activities required for each.
Audit Trail, Data Integrity & Electronic Records
Every GxP electronic record created, modified, or deleted by a non-product software system must be captured in a secure, computer-generated audit trail.
Testing Strategy Proportionate to Risk
- FDA CSA introduced unscripted, exploratory testing as a formally accepted assurance method.
- GAMP5's second edition similarly acknowledges agile, exploratory, and risk-based testing approaches alongside the traditional V-model.
Document Lifecycle Management & Version Control
Every non-product software system must have a controlled, complete, and current validation package.
Access Control, User Roles & Permissions
The access control framework for non-product software must be role-based, documented, and auditable.
Incident Management, CAPA & Deviation Handling
Incident management SOP must explicitly address software and AI system incidents, not just process deviations.
Vendor & Supplier Qualification
Supplier qualification program must be comprehensive, risk-prioritized, and regularly maintained.
Periodic Review & Continued State of Control
Periodic review must define review frequency by system risk category, the data and metrics reviewed, the criteria for determining a system is in a state of control.
4. Conclusion
The four frameworks examined here, FDA CSA, the FDA AI Guidance for Drugs and Biologics, GAMP5, and ISO 13485, converge on the same core expectations: risk-based classification, requirements traceability, change control, data integrity, and periodic review. Organizations do not need four compliance programs. They need one program built on this shared architecture, with extensions where a specific framework imposes additional requirements.